Damage associated molecular pattern molecules

Clinical Immunology

Volumn 124, Issue 1, 2007, Pages 1-4

  Lotze, Michael T ^a   Deisseroth, Albert ^a   Rubartelli, Anna ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; DNA; HIGH MOBILITY GROUP B1 PROTEIN; PROTEIN S 100; PURINE NUCLEOSIDE DERIVATIVE; RNA; S100 A8 PROTEIN; S100 A9 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

CANCER; DENDRITIC CELL; EDITORIAL; HUMAN; IMMUNOLOGY; IMMUNOREGULATION; INFLAMMATION; INJURY; ISCHEMIA; LEUKOCYTE; MACROPHAGE; MEDICAL SOCIETY; MOLECULAR BIOLOGY; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; TISSUE INJURY;

ANIMALS; CONGRESSES; DNA DAMAGE; GRANULOCYTES; HMGB1 PROTEIN; INFLAMMATION; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS; SOCIETIES, SCIENTIFIC; TOLL-LIKE RECEPTORS;

EID: 34250617016     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.02.006     Document Type: Editorial

References (35)

1. Lotze M.T., and DeMarco R.A. Dealing with Death: HMGB1 As a Novel Target for Cancer Therapy. Curr. Opin. Investig. Drugs 4 12 (2003) 1405-1409
2. Angelini G., et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc. Natl. Acad. Sci. 99 (2002) 1491-1496
3. Lotze M.T. Inflammation, necrosis, and cancer. In: Morgan D., Forssmann U., and Nakada M. (Eds). Cancer and Inflammation (2004), Birkhauser Publishing, Basel Switzerland 189-196
4. Yang D., Rosenberg H.F., Chen Q., Dyer K.D., Kurosaka K., and Oppenheim J.J. Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 102 (2003) 3396-3403
5. Yang D., Chen Q., Rosenberg H.F., Rybak S.M., Newton D.L., Wang Z.Y., Fu Q., Tchernev V.T., Wang M., Schweitzer B., Kingsmore S.F., Patel D.D., Oppenheim J.J., and Howard O.M. Human ribonuclease A superfamilty members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J. Immunol. 173 (2004) 6134-6142
6. Tang Y., Akbulut H., Maynard J., Petersen L., Fang X., Zhang W.W., Xia X., Koziol J., Linton P.J., and Deisseroth A. Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer. J. Immunol. 177 8 (2006) 5697-5707
7. Lotze M.T., and Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev., Immunol. 5 4 (2005) 331-342
8. Abraham E., Arcaroli J., Carmody A., Wang H., and Tracey K.J. HMG-1 as a mediator of acute lung inflammation. J. Immunol. 165 (2000) 2950-2954
9. Messmer D., Yang H., Telusma G., Knoll F., Li J., Messmer B., Tracey K.J., and Chiorazzi N. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173 (2004) 307-313
10. Dumitrui I.E., Baruah P., Bianchi M.E., Manfredi A.A., and Rovere-Querini P. Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35 (2005) 2184-2190
11. Yang D., Chen Q., Yang H., Tracey K.J., Bustin M., and Oppenheim J.J. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J. Leukocyte Biol. 81 (2007) 59-66
12. Park J.S., Svetkauskaite D., He Q., Kim J.Y., Strassheim D., Ishizaka A., and Abraham E. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279 (2004) 7370-7377
13. Semino C., Ceccarelli J., Lotti L.V., Torrisi M.R., Angelini G., and Rubartelli A. The maturation potential of NK cell clones toward autologous dendritic cells correlates with HMGB1 secretion. J. Leukocyte Biol. 81 1 (2007) 92-99
14. Semino C., Angelini G., Poggi A., and Rubartelli A. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood 106 2 (2005) 609-616
15. Bonaldi T., Talamo F., Scaffidi P., Ferrera D., Porto A., Bachi A., Rubartelli A., Agresti A., and Bianchi M.E. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22 20 (2003) 5551-5560
16. Gardella S., Andrei C., Ferrera D., Lotti L.V., Torrisi M.R., Bianchi M.E., and Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3 10 (2002) 995-1001
17. DeMarco R.E., Fink M.P., and Lotze M.T. Monocytes promote natural killer cell interferon-γ production in response to the endogenous danger signal HMGB1. Mol. Immunol. 42 (2005) 433-444
18. Lotze M.T., and DeMarco R.A. Dealing with death: HMGB1 as a novel target for cancer therapy. Curr. Opin. Investig. Drugs 4 12 (2003) 1405-1409
19. Bianchi M.E. PAMPs and alarmins: all we need to know about danger. J. Leukocyte Biol. 81 1 (2007) 1-5
20. Foell D., Wittkowski H., Vogl T., and Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J. Leukocyte Biol. 81 1 (2007) 28-37
21. Tsung A., Sahai R., Tanaka H., Nakao A., Fink M.P., Lotze M.T., Yang H., Li J., Tracey K.J., Geller D.A., and Billiar T.R. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med. 201 7 (2005) 1135-1143
22. Izuishi K., Tsung A., Jeyabalan G., Critchlow N.D., Li J., Tracey K.J., DeMarco R.A., Lotze M.T., Fink M.P., Geller D.A., and Billiar T.R. Cutting edge: high-mobility group box 1 preconditioning protects against liver ischemia-reperfusion injury. J. Immunol. 76 (2006) 7154-7158
23. Tsung A., Zheng N., Jeyabalan G., Izuishi K., Klune J.R., Geller D.A., Lotze M.T., Lu L., and Billiar T.R. Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J. Leukocyte Biol. 81 (2007) 119-128
24. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.T., Reinhart T.A., and Oury T.D. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 279 (2004) 50019-50024
25. Bierhaus A., Humpert P.M., Morcos M., Wendt T., Chavakis T., Arnold B., Stern D.M., and Nawroth P.P. Understanding RAGE, the receptor for advanced glycation end products. J. Mol. Med. 83 (2005) 876-886
26. Zeh III H.J., and Lotze M.T. Addicted to death: invasive cancer and the immune response to unscheduled cell death. J. Immunother. 28 1 (2005) 1-9
27. Ito N., DeMarco R.A., Mailliard R.B., Han J., Rabinowich H., Kalinski P., Beer Stolz D., Zeh H.J.I., and Lotze M.T. Cytolytic cells induce HMGB1 release from melanoma cell lines. J. Leukocyte Biol. 81 (2007) 75-83
28. Popovic P.J., DeMarco R.A., Lotze M.T., Winikoff S.E., Bartlett D.L., Krieg A.M., Guo Z.S., Brown C.K., Tracey K.J., and Zeh III H.J. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J. Immunol. 177 (2006) 8701-8707
29. Stenfeldt A.L., and Wenneras C. Danger signals derived from stressed and necrotic epithelial cells activate human eosinophils. Immunology 112 (2004) 605-614
30. Cormier S.A., Taranova A.G., Bedient C., Nguyen T., Protheroe C., Pero R., Dimina D., Ochkur S.I., O'Neill K., Colbert D., Lombari T.R., Constant S., McGarry M.P., Lee J.J., and Lee N.A. Pitoval advance: eosinophil infiltration of solid tumors is an early and persisten inflammatory host response. J. Leukocyte Biol. 79 (2006) 1131-1139
31. Meylan E., Tschopp J., and Karin M. Intracellular pattern recognition receptors in the host response. Nature 442 7098 (2006) 39-44
32. Jin S., Dipaola R.S., Matthew R., and White E. Metabolic catastrophe as a means to cancer cell death. J. Cell Sci. 120 Pt 3 (2007) 379-383
33. Kim S., Millet I., Kim H.S., Kim J.Y., Han M.S., Lee M.K., Kim K.W., Sherwin R.S., Karin M., and Lee M.S. NF-kB prevents beta cell death and autoimmune diabetes in NOD mice. Proc. Natl. Acad Sci. U. S. A. 104 6 (2007) 1913-1918
34. Brunn G.J., Wijdicks M.F., and Platt J.L. Toward a modern concept of sepsis: new answers to ancient questions. Discov. Med. 6 31 (2006) 11-17
35. Sitkovsky M.V., and Ohta A. The danger sensors that STOP the immune response: the A2 adenosine receptors?. Trends Immunol. 26 6 (2005) 299-304